Targeting patients for statin therapy for the primary prevention of vascular events: what is the best approach?
Mahoney
Elizabeth M
EM
D002097:C-Reactive Protein / Q000378:metabolism; D003362:Cost-Benefit Analysis; D003661:Decision Support Techniques; D006287:Health Planning Guidelines; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000191:economics / Q000627:therapeutic use*; D009203:Myocardial Infarction / Q000097:blood / Q000191:economics / Q000517:prevention & control*; D018579:Patient Selection; D012306:Risk; D020521:Stroke / Q000097:blood / Q000191:economics / Q000517:prevention & control*
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D002097:C-Reactive Protein